Dilution at this price, page-12

Some NIHL will come in but what amounts and how quick?

AG informed us that the NIHL portfolio continued to disappoint but it certainly did not sound like he was giving up on it.

I am hoping for more information on this come the 2017 h1 results.

It is interesting to note that we are hiring permanent NIHL post settlement staff as we speak. Why would we do that if we were not settling NIHL cases?

https://slatergordon.csod.com/ats/careersite/jobdetails.aspx?site=3&c=slatergordon&id=1733

Is is also interesting that that UK law gazette in late 2015 (sorry it is old) wrote about reforms in the NIHL industry.

https://www.lawgazette.co.uk/practice-points/noise-induced-hearing-loss-claims/5051007.article

What caught my eye in that article is this:

Ultimately, fixed costs will come in, and I suspect they will accelerate consolidation in the industrial disease market. That will mean fewer players, with massive caseloads, and making the figures pay through economies of scale.

Interesting paragraph in my view. Slater and Gordon are for sure one of the big players in the UK and also in the NIHL field. Does that mean that the future reforms predicted will benefit us going forward? It might well do.

Adding onto this we are still taking in new NIHL cases in the UK which to me indicate we are making profit here. Otherwise, why take in new NIHL cases?

So I agree that NIHL is a dark horse with some unknowns but also some positive signals.

Patience is the key

DYOR